Topic summary

Pharmaceutical compounding rules, summarised from primary sources — a second dataset

Sourcing › Regulatory MHRA research use only compounding

This is a generated summary. It shows the 8 most-liked posts from a topic of 57, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

z.onwukaTL229 Oct 2025 · edited#7

d.petrescu, post #2: Worth separating two things that the opening post runs together. Having read the whole Pharmaceutical compounding rules thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead. Go to post

Post #4 answers the question as asked. The question underneath it is different.

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

25 likes in reply to #2 9mo

BGiordanoTL2Member3 Nov 2025#14

j.baptista, post #5: Trying to state the Pharmaceutical compounding rules position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test. Go to post

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.

25 likes in reply to #5 9mo

i.balogunTL29 Nov 2025#22

CSagredo, post #20: Post-authorisation safety commitments are public and are one of the more useful sources for what a regulator considered uncertain at approval. I am aware this is the third time this month I have made this point. Go to post

Since Pharmaceutical compounding rules keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

22 likes in reply to #20 9mo

p.marchettiTL216 Nov 2025#33

Everything in post #31 holds. The case it does not cover is the one I have.

Practical note on Pharmaceutical compounding rules: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.

29 likes in reply to #2 8mo

r.laurentTL219 Nov 2025#38

e.verhoeven, post #35: Adding the boring version of Pharmaceutical compounding rules, because the interesting version keeps getting posted and the boring one is usually right. Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does. Go to post

I keep a log for Pharmaceutical compounding rules specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.

20 likes in reply to #35 8mo

a.reyesTL4 Admin21 Nov 2025 · edited#42

Answering the question post #38 raises rather than the one it answers.

24 likes 8mo

a.lindholmTL224 Nov 2025#46

Post #42 describes the usual case. This is about the unusual one.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

33 likes in reply to #5 8mo

r.mcalisterTL3Regular28 Nov 2025 · edited#54

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

23 likes 8mo

Read the full topic (57 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
What a regulator's shortage notice actually authorises — what changed since Sourcing › Regulatory research use only EMA FDA compounding Solved The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. Asking what a regulator's document…	+22	26	53k	7mo
Enforcement priorities versus written rules — does this still hold? Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says,…	+36	40	37k	11mo
Prescription requirements and telehealth models Sourcing › Regulatory FDA compounding research use only MHRA Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. Proposing that prescription requirements and telehealth models deserves a…	+91	97	5.4k	7mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…	+87	94	1.1k	21d
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since…	+28	32	640	13mo

Related topics — sharing the tags MHRA, research use only, compounding

Topic	Participants	Replies	Views	Activity
Payment mechanics and the recovery options that do not exist Sourcing › Payments documentation quality research use only payments Closed Payment mechanics and the recovery options that do not exist Writing it up because I had to work it out twice and would rather nobody else did. A payments question, with the mechanics separated from the…	+80	89	24k	9mo
Coming back to: Payment method and the leverage it gives you, ranked Sourcing › Payments payments documentation quality research use only Payment method and the leverage it gives you, ranked — setting out what I have, and where I think it stops being reliable. A payments question, with the mechanics separated from the money. What I would like…	+21	26	43k	2d
Why this community will not facilitate a group purchase Sourcing › Payments documentation quality payments research use only Asking directly, because I could not find a straight answer: Why this community will not facilitate a group purchase Currency and fees, set out so that the comparison can be checked. Quoted amount, conversion…		2	40k	3mo
Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds needs a source mislabelling research use only custom synthesis Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Melanocortin agonists, and specifically the version of it that the…	+7	11	5.5k	20mo
How compounding permissions changed when supply normalised Sourcing › Regulatory personal import EMA compounding research use only Solved Asking directly, because I could not find a straight answer: How compounding permissions changed when supply normalised I was wrong about compounding permissions in a thread last spring and I would like to…	+30	34	51k	16mo